Author:
Frantzen Léa,Cohen Jean-David,Tropé Sonia,Beck Morgane,Munos Audrey,Sittler Mariannick,Diebolt Rita,Metzler Isabelle,Arnaud Laurent,Gottenberg Jacques-Éric,Sordet Christelle
Reference22 articles.
1. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis;Bonafede;J Med Econ,2013
2. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment;Laas;Ann Rheum Dis,2006
3. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial;Jørgensen;Lancet Lond Engl,2017
4. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France;Avouac;Semin Arthritis Rheum,2017
5. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab;Sung;Rheumatol Int,2017